416 related articles for article (PubMed ID: 23903048)
1. Angiogenesis-related pathways in the pathogenesis of ovarian cancer.
Gavalas NG; Liontos M; Trachana SP; Bagratuni T; Arapinis C; Liacos C; Dimopoulos MA; Bamias A
Int J Mol Sci; 2013 Jul; 14(8):15885-909. PubMed ID: 23903048
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis.
Vera C; Tapia V; Vega M; Romero C
J Ovarian Res; 2014 Aug; 7():82. PubMed ID: 25296882
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiogenesis in cancer therapy.
Ichihara E; Kiura K; Tanimoto M
Acta Med Okayama; 2011 Dec; 65(6):353-62. PubMed ID: 22189475
[TBL] [Abstract][Full Text] [Related]
5. Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factors.
Takahashi Y; Saga Y; Koyanagi T; Takei Y; Machida S; Taneichi A; Mizukami H; Sato Y; Matsubara S; Fujiwara H
Cancer Sci; 2016 May; 107(5):629-37. PubMed ID: 26893100
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Choi HJ; Armaiz Pena GN; Pradeep S; Cho MS; Coleman RL; Sood AK
Cancer Metastasis Rev; 2015 Mar; 34(1):19-40. PubMed ID: 25544368
[TBL] [Abstract][Full Text] [Related]
7. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
8. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
10. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
13. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.
Biel NM; Siemann DW
Cancer Lett; 2016 Oct; 380(2):525-533. PubMed ID: 25312939
[TBL] [Abstract][Full Text] [Related]
16. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Makhoul I; Griffin RJ; Siegel E; Lee J; Dhakal I; Raj V; Jamshidi-Parsian A; Klimberg S; Hutchins LF; Kadlubar S
Am J Clin Oncol; 2016 Jun; 39(3):248-54. PubMed ID: 24577164
[TBL] [Abstract][Full Text] [Related]
17. Overview of anti-angiogenic agents in development for ovarian cancer.
Burger RA
Gynecol Oncol; 2011 Apr; 121(1):230-8. PubMed ID: 21215996
[TBL] [Abstract][Full Text] [Related]
18. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development.
Thapa K; Khan H; Kaur G; Kumar P; Singh TG
Biochem Biophys Res Commun; 2023 Dec; 687():149130. PubMed ID: 37944468
[TBL] [Abstract][Full Text] [Related]
20. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.
Masoumi Moghaddam S; Amini A; Morris DL; Pourgholami MH
Cancer Metastasis Rev; 2012 Jun; 31(1-2):143-62. PubMed ID: 22101807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
